Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166310 | 0.82 | LMNA (0.38) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL3166174 | 0.82 | LMNA (0.38) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL1487050 | 0.82 | LMNA (0.38) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL3828367 | 0.82 | LMNA (0.38) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL28085799 | 0.80 | LMNA (0.36) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL23176869 | 0.79 | TSHR (0.46) | TSHRCHRM2CHRM4CHRM1MAPT | |
| SCHEMBL14592888 | 0.79 | LMNA (0.39) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL14592889 | 0.79 | LMNA (0.39) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL3161142 | 0.78 | LMNA (0.35) | LMNATSHRCHRM2CHRM4CHRM5 | |
| SCHEMBL3157430 | 0.78 | LMNA (0.35) | LMNATSHRCHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989600-B2 | Bioconjugation; drug screening | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. | 2011-08-02 | — | — | US | disclosed |
| US-20090048221-A1 | Conjugates with Anti-Inflammatory Activity | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2009-02-19 | — | — | US | disclosed |
| US-20080241959-A1 | Macrolide Compounds Containing Biotin and Photo-Affinity Group for Macrolide Target Identification | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2008-10-02 | — | — | US | disclosed |
| US-20080096830-A1 | Anti-Inflammatory Macrolide Conjugates | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080241959-A1 | Macrolide Compounds Containing Biotin and Photo-Affinity Group for Macrolide Target Identification | BTD, HLCS, MRPL12 | LMNA 148/4885TSHR 1578/4885CHRM2 4266/4885 |
| US-20080096830-A1 | Anti-Inflammatory Macrolide Conjugates | NLRP3, IL1B, MPO | LMNA 1141/4885TSHR 4179/4885CHRM2 1473/4885 |
| US-20090048221-A1 | Conjugates with Anti-Inflammatory Activity | MPO, EPX, NOD1 | LMNA 190/4885TSHR 3957/4885CHRM2 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.